Stocks · Healthcare · Biotechnology
Arbutus Biopharma Corp ABUS
$4.45 -2.41% Close, Oct 2, 2026 · NASDAQ · Market cap $879.0M
High qualityInexpensive vs sectorLow risk
Next earnings report: Nov 16, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $181.7M, up 1078.8% from a year earlier, slowing from 2889.9% a quarter earlier.
- Operating margin widened to 81.0% from -444.6% a year earlier.
- The company holds net cash of $15.5M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth22Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 3%
- Revenue growth, 3-year CAGRBottom 6%
- Revenue growth accelerationBottom 1%
Quality90Exceptional
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 1%
- Gross marginTop 4%
- Operating marginTop 1%
- Cash conversion (OCF / net income)Bottom 6%
- Accruals (lower is better)Bottom 1%
- Net debt / EBITDA (lower is better)Top 33%
- Interest coverTop 1%
Value85Strong
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 2%
- Free-cash-flow yieldTop 45%
- EBITDA / enterprise valueTop 4%
- Sales / enterprise valueBottom 49%
Momentum46Neutral
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 42%
- 6-month returnBottom 42%
- 1-year return vs S&P 500Bottom 41%
- Distance from 52-week highTop 28%
- Trend checklist (0–4)Bottom 38%
Revisions72Positive
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 45%
- Upside to consensus price targetTop 39%
Stability93Exceptional
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 22%
- Maximum drawdown, 3 yearsTop 11%
- Beta vs S&P 500 (lower is better)Top 19%
- Net debt / EBITDA (lower is better)Top 33%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 2889.9% | 1078.8% | ↓ |
| Gross margin | -15.3% | 100.0% | ↑ |
| Operating margin | -444.6% | 81.0% | ↑ |
| FCF margin | -391.0% | -13.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 1078.8% | 2889.9% | ↓ | Top 3% |
| Gross margin | 100.0% | -15.3% | ↑ | Top 4% |
| Operating margin | 81.0% | -444.6% | ↑ | Top 1% |
| Net margin | 84.2% | -351.9% | ↑ | — |
| Free-cash-flow margin | -13.6% | -391.0% | ↑ | — |
| Return on invested capital | 54.3% | — | Top 1% | |
| Revenue growth, 3-year CAGR | -28.8% | — | Bottom 6% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- -0.16×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 64.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 3.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +16357.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.10×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1937.1×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.96%
- Shareholder yield
- -1.96%
- Share count change, 1 year
- +2.6%
- Share count change, 3-year CAGR
- +5.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 12, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -0.7%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $8.50
- Target vs current price
- +91.0%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 80%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | -50.0% | -1.7% | +3.6% | +10.7% | — |
| May 13, 2026 | +3000.0% | +0.0% | -2.6% | -4.4% | +7.4% |
| Mar 23, 2026 | +71.5% | +4.2% | +1.2% | +8.5% | +3.5% |
| Nov 13, 2025 | +28.6% | -5.8% | -11.8% | -3.5% | -14.0% |
| Aug 6, 2025 | +150.0% | +1.8% | -0.3% | +15.2% | +35.2% |
| May 14, 2025 | -44.4% | -0.9% | +0.6% | +9.7% | +6.6% |
| Mar 27, 2025 | +12.5% | -2.4% | +4.8% | -0.3% | +1.8% |
| Nov 6, 2024 | +0.0% | -1.0% | -8.1% | -5.6% | -15.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.03 | -$0.02 | -50.0% | $1.0M |
| May 13, 2026 | $0.87 | -$0.03 | +3000.0% | $179.1M |
| Mar 23, 2026 | -$0.01 | -$0.04 | +71.5% | $1.1M |
| Nov 13, 2025 | -$0.04 | -$0.06 | +28.6% | $529,000 |
| Aug 6, 2025 | $0.01 | -$0.02 | +150.0% | $10.7M |
| May 14, 2025 | -$0.13 | -$0.09 | -44.4% | $1.8M |
| Mar 27, 2025 | -$0.07 | -$0.08 | +12.5% | $1.6M |
| Nov 6, 2024 | -$0.10 | -$0.10 | +0.0% | $1.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 5.7× | — | — | Top 2% |
| P/E (forward) | 6.0× | — | — | — |
| EV / EBITDA | 5.6× | — | — | Top 4% |
| EV / Sales | 4.75× | — | — | Bottom 49% |
| Free-cash-flow yield | -2.80% | — | — | Top 45% |
| Earnings yield | 17.54% | — | — | Top 2% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +2.0%
- 200-day average slope (20 days)
- +1.1%
- Distance from 50-day average
- -7.9%
- Distance from 200-day average
- -2.0%
- RSI (14)
- 27.7
- Relative volume
- 1.15×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 39.7%
- Volatility vs own 5-year history
- 19th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.56
- Correlation with S&P 500
- 0.22
- Current drawdown from 1-year high
- -14.8%
- Maximum drawdown, 3 years
- -36.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 15, 2020 | Oct 23, 2023 | -66.0% | 717 days | 675 days (Jul 6, 2026) |
| Nov 30, 2020 | Dec 9, 2020 | -24.7% | 7 days | 3 days (Dec 14, 2020) |
| Jul 8, 2026 | Jul 29, 2026 | -17.8% | 15 days | Not yet recovered |
| Oct 7, 2020 | Nov 2, 2020 | -16.9% | 18 days | 7 days (Nov 11, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $879.0M
- P/E (TTM)
- 5.7
- EPS, diluted (TTM)
- $0.78
- Revenue (TTM)
- $181.7M
- 52-week range
- $3.50 – $5.45
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Gross profit | $11.0M | $39.0M | $18.1M | $6.2M | $13.7M |
| Operating income | -$73.5M | -$65.5M | -$78.1M | -$76.3M | -$27.1M |
| Net income | -$76.2M | -$69.5M | -$72.8M | -$69.9M | -$33.5M |
| EPS (diluted) | -$0.73 | -$0.46 | -$0.44 | -$0.38 | -$0.17 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.6M | $1.8M | $10.7M | $529,000 | $1.1M | $179.1M | $1.0M |
| Net income | -$19.7M | -$12.5M | -$24.5M | $2.5M | -$7.7M | -$3.8M | $169.7M | -$5.1M |
| EPS (diluted) | -$0.10 | -$0.07 | -$0.13 | $0.01 | -$0.04 | -$0.02 | $0.87 | -$0.03 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$67.5M | -$35.4M | -$85.9M | -$64.8M | -$39.6M |
| Capital expenditure | -$809,000 | -$512,000 | -$1.0M | -$182,000 | $0 |
| Free cash flow | -$68.3M | -$35.9M | -$86.9M | -$65.0M | -$39.6M |
| Dividends paid | -$12.1M | $0 | $0 | $0 | $0 |
| Net share buybacks | $134.7M | $20.3M | $29.9M | $44.1M | $5.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $92.6M
- Total assets
- $274.0M
- Total liabilities
- $15.3M
- Total debt
- $3.6M
- Net debt
- -$15.5M
- Shareholders’ equity
- $258.7M
As of Jun 30, 2026 (filed Aug 12, 2026).
Short interest
- Shares sold short
- 18,484,910
- Days to cover
- 5.01
- Change vs previous report
- -2.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Nov 4, 2010
- 1-for-5